Carmen Mikacenic1, Elizabeth E Hansen, Frank Radella, Sina A Gharib, Renee D Stapleton, Mark M Wurfel. 1. 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA.2Department of Anesthesia and Pain Medicine, University of Washington, Seattle, WA.3Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Vermont, Burlington, VT.
Abstract
OBJECTIVE: Interleukin-17A is a proinflammatory cytokine known to play a role in host defense and pathologic inflammation in murine models of lung injury. The relationship between interleukin-17A and inflammation in human lung injury is unknown. Our primary objective was to determine whether interleukin-17A levels are associated with alveolar measures of inflammation and injury in patients with acute respiratory distress syndrome. Our secondary objective was to test whether interleukin-17A levels are associated with acute respiratory distress syndrome-related outcomes. DESIGN: Observational study. SETTING: Six North American medical centers. PATIENTS: We studied two groups of patients with acute respiratory distress syndrome: 1) patients previously enrolled in a placebo-controlled clinical trial of omega-3 fatty acids performed at five North American medical centers (n = 86, acute respiratory distress syndrome 1), and 2) patients with systemic inflammatory response syndrome admitted to an ICU who developed acute respiratory distress syndrome (n = 140, acute respiratory distress syndrome 2). In acute respiratory distress syndrome 1, we used paired serum and bronchoalveolar lavage fluid samples obtained within 48 hours of acute respiratory distress syndrome onset, whereas in acute respiratory distress syndrome 2, we used plasma obtained within the first 24 hours of ICU admission. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We measured circulating interleukin-17A in acute respiratory distress syndrome 1 and acute respiratory distress syndrome 2. We also measured interleukin-17A, neutrophil counts, and total protein in bronchoalveolar lavage fluid from acute respiratory distress syndrome 1. We found that bronchoalveolar lavage interleukin-17A was strongly associated with higher bronchoalveolar lavage percent neutrophils (p < 0.001) and bronchoalveolar lavage total protein (p < 0.01) in acute respiratory distress syndrome1. In both acute respiratory distress syndrome 1 and acute respiratory distress syndrome 2, elevated interleukin-17A was associated with higher Sequential Organ Failure Assessment scores (p < 0.05). CONCLUSIONS: Elevated circulating and alveolar levels of interleukin-17A are associated with increased percentage of alveolar neutrophils, alveolar permeability, and organ dysfunction in acute respiratory distress syndrome.
OBJECTIVE:Interleukin-17A is a proinflammatory cytokine known to play a role in host defense and pathologic inflammation in murine models of lung injury. The relationship between interleukin-17A and inflammation in humanlung injury is unknown. Our primary objective was to determine whether interleukin-17A levels are associated with alveolar measures of inflammation and injury in patients with acute respiratory distress syndrome. Our secondary objective was to test whether interleukin-17A levels are associated with acute respiratory distress syndrome-related outcomes. DESIGN: Observational study. SETTING: Six North American medical centers. PATIENTS: We studied two groups of patients with acute respiratory distress syndrome: 1) patients previously enrolled in a placebo-controlled clinical trial of omega-3 fatty acids performed at five North American medical centers (n = 86, acute respiratory distress syndrome 1), and 2) patients with systemic inflammatory response syndrome admitted to an ICU who developed acute respiratory distress syndrome (n = 140, acute respiratory distress syndrome 2). In acute respiratory distress syndrome 1, we used paired serum and bronchoalveolar lavage fluid samples obtained within 48 hours of acute respiratory distress syndrome onset, whereas in acute respiratory distress syndrome 2, we used plasma obtained within the first 24 hours of ICU admission. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We measured circulating interleukin-17A in acute respiratory distress syndrome 1 and acute respiratory distress syndrome 2. We also measured interleukin-17A, neutrophil counts, and total protein in bronchoalveolar lavage fluid from acute respiratory distress syndrome 1. We found that bronchoalveolar lavage interleukin-17A was strongly associated with higher bronchoalveolar lavage percent neutrophils (p < 0.001) and bronchoalveolar lavage total protein (p < 0.01) in acute respiratory distress syndrome1. In both acute respiratory distress syndrome 1 and acute respiratory distress syndrome 2, elevated interleukin-17A was associated with higher Sequential Organ Failure Assessment scores (p < 0.05). CONCLUSIONS: Elevated circulating and alveolar levels of interleukin-17A are associated with increased percentage of alveolar neutrophils, alveolar permeability, and organ dysfunction in acute respiratory distress syndrome.
Authors: Abraham B Roos; Sanjay Sethi; Jake Nikota; Catherine T Wrona; Michael G Dorrington; Caroline Sandén; Carla M T Bauer; Pamela Shen; Dawn Bowdish; Christopher S Stevenson; Jonas S Erjefält; Martin R Stampfli Journal: Am J Respir Crit Care Med Date: 2015-08-15 Impact factor: 21.405
Authors: Qun Wu; Richard J Martin; John G Rino; Rachel Breed; Raul M Torres; Hong Wei Chu Journal: Microbes Infect Date: 2006-12-15 Impact factor: 2.700
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Carolyn S Calfee; Mark D Eisner; Lorraine B Ware; B Taylor Thompson; Polly E Parsons; Arthur P Wheeler; Anna Korpak; Michael A Matthay Journal: Crit Care Med Date: 2007-10 Impact factor: 7.598
Authors: Mark M Wurfel; Anthony C Gordon; Tarah D Holden; Frank Radella; Jeanna Strout; Osamu Kajikawa; John T Ruzinski; Gail Rona; R Anthony Black; Seth Stratton; Gail P Jarvik; Adeline M Hajjar; Deborah A Nickerson; Mark Rieder; Jonathan Sevransky; James P Maloney; Marc Moss; Greg Martin; Carl Shanholtz; Joe G N Garcia; Li Gao; Roy Brower; Kathleen C Barnes; Keith R Walley; James A Russell; Thomas R Martin Journal: Am J Respir Crit Care Med Date: 2008-07-17 Impact factor: 21.405
Authors: Dominique M A Bullens; Els Truyen; Liesbeth Coteur; Ellen Dilissen; Peter W Hellings; Lieven J Dupont; Jan L Ceuppens Journal: Respir Res Date: 2006-11-03
Authors: Hiroaki Takatori; Yuka Kanno; Wendy T Watford; Cristina M Tato; Greta Weiss; Ivaylo I Ivanov; Dan R Littman; John J O'Shea Journal: J Exp Med Date: 2008-12-29 Impact factor: 14.307
Authors: Marie-Laure Michel; Alexandre Castro Keller; Christophe Paget; Masakazu Fujio; François Trottein; Paul B Savage; Chi-Huey Wong; Elke Schneider; Michel Dy; Maria C Leite-de-Moraes Journal: J Exp Med Date: 2007-04-30 Impact factor: 14.307
Authors: Tariq A Bhat; Suresh G Kalathil; Noel Leigh; Thivanka Muthumalage; Irfan Rahman; Maciej L Goniewicz; Yasmin M Thanavala Journal: Nicotine Tob Res Date: 2021-06-08 Impact factor: 4.244
Authors: Anthony J Esposito; Pavan K Bhatraju; Renee D Stapleton; Mark M Wurfel; Carmen Mikacenic Journal: Crit Care Date: 2017-12-14 Impact factor: 9.097